Senzime Launches Medical Affairs Division and Education Platform to Drive Transformation in Anesthesia Monitoring

UPPSALA, Sweden and ST. LOUIS, May 13, 2025 /PRNewswire/ -- Senzime, a global leader in precision-based perioperative monitoring solutions, today announced the formation of a new Medical Affairs division and the parallel launch of Senzime Academy—an open-access education platform designed to advance the implementation of guideline-supported neuromuscular monitoring worldwide.

"These initiatives aim to drive the next wave of clinical transformation in anesthesia care, as Senzime continues to strengthen our role not only as a device innovator, but as a scientific and educational partner," said Philip Siberg, CEO of Senzime. "Our new Medical Affairs team and educational platform reflect our commitment to partnering with providers to implement evidence-based practices that elevate patient outcomes."

Building a Global Clinical Community
Senzime's new Medical Affairs division will serve as a hub for collaboration with leading academic centers, anesthesia providers, and perioperative teams. Its mission is to translate clinical research into real-world practice, support best-in-class implementation, and elevate global awareness about the ongoing risks of residual neuromuscular block (rNMB). The division is led by Jen Sanders, Director of Clinical and Medical Affairs.

Addressing the Real-World Needs of Anesthesia Teams
To support widespread adoption of neuromuscular monitoring, Senzime Academy offers clinicians on-demand training on quantitative train-of-four (TOF) monitoring and best practices for TetraGraph® use. The digital platform includes video modules, clinical case examples, and implementation guides for both adult and pediatric care settings.

Built on 40+ Years of Scientific Research
Senzime's flagship TetraGraph system is the result of over four decades of neuromuscular monitoring research, translated into a clinically robust, EMG-based platform purpose-built to meet the demands of modern surgery. Its proprietary TOF monitoring technology is clinically evaluated in 19 peer-reviewed publications, making it the most studied EMG system available today. TetraGraph is used in over 3,500 operating rooms worldwide, supporting compliance with best practices outlined by the American Society of Anesthesiologists (ASA) and the European Society of Anaesthesiology and Intensive Care (ESAIC).

More information how Senzime's solutions can be used across specialized clinical applications, such as robotic-assisted surgeries, pediatrics, and enhanced recovery after surgery (ERAS), is available at https://senzime.com.

More information about Senzime Academy is available at https://www.senzime.com/en/explore-senzime-academy-anytime-anywhere.

For further information, please contact:
Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: [email protected]

About Senzime
Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.

Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at senzime.com.

SOURCE Senzime